Clinical Trial Update: Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab combined with double doses of icotinib in advanced non-small cell lung cancer with EGFR L858R mutation has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• icotinib (icotinib)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Carcinoma, Non-Small-Cell Lung, Bevacizumab | Phase 2 | Status: COMPLETED